The Food and Drug Administration intends to update its Risk Evaluation and Mitigation Strategy requirements for extended-release and long-acting opioid analgesics, and extend the same requirements to immediate-release opioid analgesic products, FDA Commissioner Scott Gottlieb, M.D., announced this week. The existing REMS requires companies that manufacture extended-release and long-acting opioid analgesics to make education programs available to prescribers and patients. According to Gottlieb, the new REMS will modify the prescriber education blueprint to include more information on pain management, safe use of opioid analgesics, addiction medicine and opioid use disorders. The REMS also will require manufacturers to make training available to more than physician prescribers, such as nurses and pharmacists involved in pain management. In addition, he said the agency is exploring whether provider education should be mandatory. According to FDA, about 90% of opioid prescriptions in the U.S. are for immediate-release formulations.

Related News Articles

Headline
President Trump yesterday signed the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (S. 1379), which cleared Congress earlier this month.
Perspective
Integrating behavioral health services to treat the whole patient across the continuum of care is vital to improving health in our communities — and it’s just…
Headline
The House of Representatives last night passed legislation (H.R. 3253) that includes an AHA-supported provision that would extend the Community Mental Health…
Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Centers for Disease Control and Prevention today activated its Emergency Operations Center to support the interagency response to the Ebola outbreak in…
Headline
The World Health Organization has confirmed the first cases of Ebola in Uganda since 2013.